Moving on With Monoamine Oxidase Inhibitors.
作者信息
Bodkin J Alexander, Dunlop Boadie W
机构信息
Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont (Bodkin); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Dunlop).
出版信息
Focus (Am Psychiatr Publ). 2021 Jan;19(1):50-52. doi: 10.1176/appi.focus.20200046. Epub 2021 Jan 25.
Abstract
摘要
相似文献
1
Moving on With Monoamine Oxidase Inhibitors.继续探讨单胺氧化酶抑制剂
Focus (Am Psychiatr Publ). 2021 Jan;19(1):50-52. doi: 10.1176/appi.focus.20200046. Epub 2021 Jan 25.
2
Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update.单胺氧化酶-B 抑制剂作为潜在的神经治疗药物：概述与更新。
Med Res Rev. 2019 Sep;39(5):1603-1706. doi: 10.1002/med.21561. Epub 2019 Jan 2.
3
Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.单胺氧化酶、单胺氧化酶抑制剂与惊恐障碍。
J Neural Transm Suppl. 1989;28:53-63.
4
The evaluation of 1-tetralone and 4-chromanone derivatives as inhibitors of monoamine oxidase.评价 1-四氢萘酮和 4-色满酮衍生物作为单胺氧化酶抑制剂。
Mol Divers. 2021 Feb;25(1):491-507. doi: 10.1007/s11030-020-10143-w. Epub 2020 Sep 24.
5
Substrate selectivity of monoamine oxidase A, monoamine oxidase B, diamine oxidase, and semicarbazide-sensitive amine oxidase in COS-1 expression systems.COS-1表达系统中，单胺氧化酶A、单胺氧化酶B、二胺氧化酶和氨基脲敏感胺氧化酶的底物选择性。
Biol Pharm Bull. 2006 Dec;29(12):2362-6. doi: 10.1248/bpb.29.2362.
6
Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.A型单胺氧化酶与rasagiline（B 型单胺氧化酶抑制剂）诱导神经保护 Bcl-2 有关。
J Neural Transm (Vienna). 2012 Apr;119(4):405-14. doi: 10.1007/s00702-011-0730-6. Epub 2011 Nov 8.
7
Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.慢性单胺氧化酶-B 抑制剂治疗可阻断单胺氧化酶-A 酶活性。
J Neural Transm (Vienna). 2014 Apr;121(4):379-83. doi: 10.1007/s00702-013-1120-z. Epub 2013 Nov 23.
8
Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework.基于特权 2-咪唑啉分子框架的新型单胺氧化酶抑制剂。
Bioorg Med Chem Lett. 2019 Jan 1;29(1):40-46. doi: 10.1016/j.bmcl.2018.11.018. Epub 2018 Nov 9.
9
Indanones as high-potency reversible inhibitors of monoamine oxidase.茚满酮类作为单胺氧化酶的高效可逆抑制剂。
ChemMedChem. 2015 May;10(5):862-73. doi: 10.1002/cmdc.201500059. Epub 2015 Mar 27.
10
The synthesis and evaluation of sesamol and benzodioxane derivatives as inhibitors of monoamine oxidase.芝麻酚和苯并二恶烷衍生物作为单胺氧化酶抑制剂的合成与评价
Bioorg Med Chem Lett. 2015 May 1;25(9):1896-900. doi: 10.1016/j.bmcl.2015.03.040. Epub 2015 Mar 20.
引用本文的文献
1
Different Effects of SSRIs, Bupropion, and Trazodone on Mitochondrial Functions and Monoamine Oxidase Isoform Activity.选择性5-羟色胺再摄取抑制剂、安非他酮和曲唑酮对线粒体功能及单胺氧化酶同工酶活性的不同影响。
Antioxidants (Basel). 2023 Jun 2;12(6):1208. doi: 10.3390/antiox12061208.
2
Recognition and Management of Serotonin Toxidrome in the Emergency Department-Case Based Review.急诊科5-羟色胺中毒综合征的识别与处理——基于病例的综述
J Pers Med. 2022 Dec 15;12(12):2069. doi: 10.3390/jpm12122069.
3
Analysis of the Underlying Mechanism of the Jiu Wei Zhen Xin Formula for Treating Generalized Anxiety Disorder Based on Network Pharmacology of Traditional Chinese Medicine.基于中医网络药理学分析九味镇心方治疗广泛性焦虑障碍的潜在机制
Evid Based Complement Alternat Med. 2022 May 29;2022:7761852. doi: 10.1155/2022/7761852. eCollection 2022.
4
Navigating the Novel Psychotropics.探索新型精神药物
Focus (Am Psychiatr Publ). 2021 Jan;19(1):1-2. doi: 10.1176/appi.focus.20200044. Epub 2021 Jan 25.
本文引用的文献
1
Atypical depression: useful concept, but it's time to revise the DSM-IV criteria.非典型性抑郁症：有用的概念，但现在是时候修改 DSM-IV 标准了。
Neuropsychopharmacology. 2009 Dec;34(13):2633-41. doi: 10.1038/npp.2009.100. Epub 2009 Sep 9.
2
The role of dopamine in the pathophysiology of depression.多巴胺在抑郁症病理生理学中的作用。
Arch Gen Psychiatry. 2007 Mar;64(3):327-37. doi: 10.1001/archpsyc.64.3.327.
3
Selegiline transdermal system: in the treatment of major depressive disorder.司来吉兰透皮系统：用于治疗重度抑郁症。
Drugs. 2007;67(2):257-65; discussion 266-7. doi: 10.2165/00003495-200767020-00006.
4
A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status.米氮平对人体血清素能作用的系统评价：对其双重作用状态的影响。
Hum Psychopharmacol. 2006 Mar;21(2):117-25. doi: 10.1002/hup.750.
5
A survey of prescribing practices for monoamine oxidase inhibitors.
Psychiatr Serv. 1999 Jul;50(7):945-7. doi: 10.1176/ps.50.7.945.
6
The making of a user friendly MAOI diet.一份便于使用的单胺氧化酶抑制剂饮食的制定。
J Clin Psychiatry. 1996 Mar;57(3):99-104.
7
MAOIs in the contemporary treatment of depression.单胺氧化酶抑制剂在当代抑郁症治疗中的应用
Neuropsychopharmacology. 1995 May;12(3):185-219. doi: 10.1016/0893-133X(94)00058-8.
8
The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial.
Arch Gen Psychiatry. 1983 Jun;40(6):657-61. doi: 10.1001/archpsyc.1983.04390010067008.
9
Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders.
Am J Psychiatry. 1988 Mar;145(3):306-11. doi: 10.1176/ajp.145.3.306.
10
Management of monoamine oxidase inhibitor-associated insomnia with trazodone.用曲唑酮治疗单胺氧化酶抑制剂相关失眠症
J Clin Psychopharmacol. 1989 Feb;9(1):42-5.
Zotero 插件